NeuMedics
NeuMedics is an early-stage, pre-revenue biopharmaceutical company developing NM320, a first-in-class modified-tetracycline topical eye drop for dry AMD and related retinal diseases, intended to be advanced via pharmaceutical licensing or co-development partnerships rather than independent commercialization.
- Company typePrivate
- Founded2008
- HeadquartersSeattle, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuMedics does
NeuMedics Inc. is an early-stage, privately held biopharmaceutical company developing NM320, a first-in-class topical eye-drop therapy for retinal disease. The lead indication is dry age-related macular degeneration (AMD), with diabetic retinopathy and other oxidative-stress-driven retinal conditions positioned as follow-on opportunities. The company was formed in 2008 in Washington State and now operates from a New York headquarters; it remains sub-scale at 1–10 employees and is led by a small executive team headed by CEO William D. Schwieterman, M.D., with Mark L. Nelson, Ph.D. as VP of Chemistry and Iain Duncan as COO.
NM320 is built on a modified tetracycline scaffold derived from minocycline, combined with a proprietary lipophilic microemulsion formulation designed to deliver therapeutic drug levels to the posterior retina without intravitreal injection. The mechanism targets mitochondrial dysfunction and oxidative stress in retinal pigment epithelial cells, aiming to intervene before irreversible degeneration rather than treating late-stage disease symptomatically. Preclinical work has demonstrated retinal pigment epithelial cell protection in an AMD mouse model with topical administration, but no human clinical efficacy data is disclosed in the source material.
NeuMedics is pre-revenue and intends to monetize through pharmaceutical licensing, co-development, or royalty arrangements rather than independent commercialization. The company's GTM motion is enterprise partnership outreach to larger pharma companies willing to advance NM320 through clinical development and eventual market launch. Capitalization is thin: the only disclosed funding event is a $87,950 financing in May 2009, with no institutional investors, parent company, or recent venture rounds identified in the source data, leaving the company's near-term clinical progression contingent on a future partnership or financing transaction.
NeuMedics firmographics
Firmographics- Name
- NeuMedics
- Legal name
- NeuMedics Inc.
- Website
- https://neumedics.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NeuMedics is an early-stage, pre-revenue biopharmaceutical company developing NM320, a first-in-class modified-tetracycline topical eye drop for dry AMD and related retinal diseases, intended to be advanced via pharmaceutical licensing or co-development partnerships rather than independent commercialization.
- Ownership category
- akta.pro rank
NeuMedics industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals / Retinal Disease Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)
- akta.pro primary industry
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
- akta.pro secondary industry
- Retina & Vitreous Specialists (HLAKAKAE)
Keywords
Where NeuMedics is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeuMedics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical licensing/partnerships: Pre-revenue biotech company. Revenue model will likely involve licensing NM320 to larger pharmaceutical companies for clinical development and commercialization, or co-development partnerships.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
NeuMedics product offering
Product offeringCore offering
NeuMedics develops NM320, a first-in-class topical eye drop therapy for retinal diseases—primarily dry age-related macular degeneration (AMD)—built on a modified tetracycline scaffold combined with a proprietary lipophilic microemulsion delivery system. The therapy is designed to deliver therapeutic drug levels to the posterior retina without intravitreal injections, targeting mitochondrial dysfunction and oxidative stress to protect retinal cells before irreversible degeneration.
Product overview
NeuMedics is an early-stage biotechnology company developing a single core product, NM320, a first-in-class topical eye drop therapy for retinal diseases, particularly dry age-related macular degeneration. NM320 is built on a proprietary platform combining a modified tetracycline scaffold with a lipophilic microemulsion delivery system designed to deliver therapeutic drug levels to the retina without injections. The company's focus is on intervening early in disease progression by targeting mitochondrial dysfunction and oxidative stress at the cellular level.
Differentiator
Problem solved
Functional benefit
Brands
- NM320: A first-in-class, tetracycline-based, retinal therapy designed to protect cells before irreversible degeneration. Derived from minocycline, NM320 is a topical eye drop therapy for dry age-related macular degeneration (AMD) that delivers therapeutic drug levels to the retina without injections.
Products and services
- NM320 NM320 is a first-in-class, tetracycline-based retinal therapy derived from minocycline, delivered as a topical eye drop via a proprietary lipophilic microemulsion. It is designed to stabilize mitochondrial dysfunction, reduce oxidative stress, and protect retinal cells before irreversible degeneration in dry age-related macular degeneration (AMD), with broader potential in diabetic retinopathy and other retinal diseases driven by oxidative stress.
Quantifiable outcome
- Preclinical evidence of retinal pigment epithelial cell protection in established AMD mouse model with topical administration
Companies that use NeuMedics
Customer profileSegments3 records
Ideal customer profiles1 record
NeuMedics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
NeuMedics partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights4 records
NeuMedics competitors and assessment
Company assessmentDirect peers
- Apellis Pharmaceuticals: Apellis developed and commercialized Syfovre (pegcetacoplan), the first FDA-approved therapy for geographic atrophy secondary to dry AMD. It is the most directly comparable late-stage retinal-degeneration peer and serves as a benchmark for regulatory pathway, commercial dynamics, and competitive positioning versus NM320.
- Iveric Bio (Astellas): Iveric Bio developed Izervay (avacincaptad pegol), FDA-approved for geographic atrophy in dry AMD and acquired by Astellas in 2023. Direct clinical and commercial peer for the same indication NeuMedics targets, providing useful read-throughs on partnership economics and label dynamics.
- Annexon, Inc. Annexon is developing ANX007, an investigational therapy for geographic atrophy and other retinal neurodegenerative diseases, with a neuroprotective mechanism comparable in spirit to NM320's upstream targeting approach. Comparable size and clinical-stage profile make it a useful benchmarking peer.
- Alkeus Pharmaceuticals: Alkeus is developing gildeuretinol (ALK-001) for Stargardt disease and exploring age-related macular degeneration, with a focus on reducing toxic vitamin A dimers implicated in retinal degeneration. Comparable emerging retinal-disease developer with a non-injection therapeutic angle.
- Kodiak Sciences: Kodiak Sciences developed tarcocimab (KSI-301), an anti-VEGF therapy for retinal vascular diseases, with a focus on durability and reduced injection burden. Direct peer in targeting retinal diseases with novel mechanisms aiming to displace the intravitreal injection paradigm.
Emerging players
- Lineage Cell Therapeutics: Lineage is developing OpRegen, an allogeneic retinal pigment epithelium cell therapy for dry AMD with geographic atrophy. Although cell-therapy based rather than small molecule, it is targeting the same unmet need and provides a useful read on emerging modalities competing with NM320.
- Aldeyra Therapeutics: Aldeyra is developing reproxalap and other small-molecule therapies for ocular inflammatory conditions including dry eye disease, with adjacencies to retinal indications. Comparable small-cap, small-molecule ophthalmology developer using non-invasive topical approaches.
- Ocular Therapeutix: Ocular Therapeutix develops sustained-release ophthalmic drug delivery technologies (e.g., Dextenza, OTX-TKI) targeting retinal and anterior-segment diseases. Most relevant peer for novel drug-delivery approaches in ophthalmology, sharing NeuMedics' focus on reducing treatment burden versus conventional delivery.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept), the leading intravitreal anti-VEGF therapy for wet AMD, diabetic retinopathy, and related retinal conditions. As the dominant incumbent in the retinal injection market, Eylea defines the standard-of-care NM320 aims to disrupt with non-invasive delivery.
- Genentech (Roche): Genentech markets Lucentis (ranibizumab) and Vabysmo (faricimab), foundational anti-VEGF therapies for wet AMD and diabetic eye disease. Represents the established large-pharma competitive backdrop against which NM320's differentiated mechanism and delivery must compete.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
NeuMedics social profiles
Digital presenceNeuMedics financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuMedics leadership team
Management profileNumber of profiles
Profiles3 records
NeuMedics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuMedics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuMedics
What does NeuMedics do?
NeuMedics develops NM320, a first-in-class topical eye drop therapy for retinal diseases—primarily dry age-related macular degeneration (AMD)—built on a modified tetracycline scaffold combined with a proprietary lipophilic microemulsion delivery system. The therapy is designed to deliver therapeutic drug levels to the posterior retina without intravitreal injections, targeting mitochondrial dysfunction and oxidative stress to protect retinal cells before irreversible degeneration.
Is NeuMedics a public or private company?
NeuMedics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NeuMedics founded?
NeuMedics was founded in 2008. It employs 1 to 10 people.
Where is NeuMedics based?
NeuMedics is headquartered in Seattle, United States, in the North America region.
How does NeuMedics make money?
One revenue line is on record: pharmaceutical licensing/partnerships.
Who are NeuMedics's main competitors?
Direct peers on record are Apellis Pharmaceuticals, Iveric Bio (Astellas), Annexon, Inc., Alkeus Pharmaceuticals and Kodiak Sciences. Emerging players are Lineage Cell Therapeutics, Aldeyra Therapeutics and Ocular Therapeutix. Broad incumbents are Regeneron Pharmaceuticals and Genentech (Roche).
Does NeuMedics have an API?
No public API is recorded for NeuMedics.
What industry is NeuMedics in?
NeuMedics's product category is Ophthalmic Pharmaceuticals / Retinal Disease Therapeutics. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 3254 and its SIC code is 2834.